FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANG	ES IN BEI	NEFICIAL (OWNERSI	HIP

OMB APP	ROVAL
0145 11	2005.0

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Burns Brian R (Last) (First) (Middle) 400 WOOD ROAD (Street)				3. Da 10/2	2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE] 3. Date of Earliest Transaction (Month/Day/Year) 10/20/2015 4. If Amendment, Date of Original Filed (Month/Day/Year)								(Check	EVP, Global QA/RA 6. Individual or Joint/Group Filing (Check Applicab							
BRAINTF (City)	REE MA		2184 Zip)												X	Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transa Date			2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		es Acquir	ed (A)) or	Beneficially Owned Followin		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership							
								Co	de V	$, \neg$	Amount (A) or (D)		r F	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Common Stock 10/2				10/20)/2015		A	Α	\exists	3,909(1)	<u> </u>		\$0.01	15,719			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	I. Fransaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea				7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable		Expiration Date	Title	or Nu of	ımber						
Performance Shares	\$0	10/20/2015			Α		7,819		09/30/	2018 ⁽²⁾ 12		12/31/2018	Common Stock 7,		,819	\$0	7,819	9	D		
Non- qualified Stock Option (Right to	\$31.97	10/20/2015			A		17,186		10/20/	/2016 ⁽³	3)	10/20/2022	Common Stock	17	7,186	\$31.97	17,18	6	D		

Explanation of Responses:

- 1. Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
- 2. Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Standard & Poors Health Care Equipment Index. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2015 and September 30, 2018. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).
- 3. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

/s/ Alexander P. Steffan, attorney-in-fact for Mr. Burns

10/23/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.